A Claudio Cuello, OC, MD, DSc, FRSC, FMedSci, FMedSci
|1985-||Pharmacology And Therapeutics||McGill University, Montreal, QC, Canada|
Area:Alzheimer's Disease, cognitive behavior, neurochemistry, immunocytochemistry, neuropharmacology and molecular biology.
Google:"A Claudio Cuello"
Since 2003, he has been the Charles E. Frosst/Merck endowed Chair in Pharmacology at McGill University. He leads a research team on multidisciplinary aspects (cognitive behavior, neurochemistry, immunocytochemistry, neuropharmacology and molecular biology) of brain aging and Alzheimer’s disease neuropathology. The Cuello Lab is comprised of talented and motivated colleagues focused on unravelling the earliest biochemical-pathological events of the Alzheimer’s pathology as well as searching for early biomarkers and novel experimental therapies to arrest or revert the early Alzheimer’s pathology. His group has recently made important contributions to the understanding of CNS trophic factor deregulation both in Alzheimer’s disease and in Down syndrome.
Mean distance: 13.39 (cluster 11)
ParentsSign in to add mentor
|Amanda Pellegrino de Iraldi||grad student||Universidad de Buenos Aires|
|Eduardo De Robertis||grad student||UBA|
|William Francis Ganong||post-doc||University of California in San Francisco (UCSF) (Terrestrial Ecology Tree)|
|Fernando Orioli||post-doc||Universidad de Buenos Aires|
|Umberto Tramezzani||post-doc||IBYME-CONICET Buenos Aires|
ChildrenSign in to add trainee
|Lisi Flores Aguilar||grad student||McGill|
|John V. Priestley||grad student||Oxford|
|Michael V. Sofroniew||grad student||Johns Hopkins, McGill University|
|Morgan Foret||grad student||2015-||McGill|
|Tak Pan Wong||grad student||1995-2001||McGill|
|Maria T. Ferretti||grad student||2012||McGill|
|Edward Nesbitt Wilson||grad student||2011-2016||McGill University School of Medicine|
|Valentina Echeverria Moran||post-doc||2001-2003||McGill|
CollaboratorsSign in to add collaborator
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.
|Hampel H, Vergallo A, Caraci F, et al. (2020) Future avenues for Alzheimer's disease detection and therapy: Liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery. Neuropharmacology. 108081|
|Hampel H, Caraci F, Cuello AC, et al. (2020) A Path Toward Precision Medicine for Neuroinflammatory Mechanisms in Alzheimer's Disease. Frontiers in Immunology. 11: 456|
|Welikovitch LA, Do Carmo S, Maglóczky Z, et al. (2020) Early intraneuronal amyloid triggers neuron-derived inflammatory signaling in APP transgenic rats and human brain. Proceedings of the National Academy of Sciences of the United States of America|
|Wilson EN, Do Carmo S, Welikovitch LA, et al. (2019) NP03, a Microdose Lithium Formulation, Blunts Early Amyloid Post-Plaque Neuropathology in McGill-R-Thy1-APP Alzheimer-Like Transgenic Rats. Journal of Alzheimer's Disease : Jad|
|Hampel H, Vergallo A, Afshar M, et al. (2019) Blood-based systems biology biomarkers for next-generation clinical trials in Alzheimer's disease . Dialogues in Clinical Neuroscience. 21: 177-191|
|Martino Adami PV, Nichtová Z, Weaver DB, et al. (2019) Perturbed mitochondria-ER contacts in live neurons modelling Alzheimer's disease amyloid pathology. Journal of Cell Science|
|Pascoal TA, Mathotaarachchi S, Kang MS, et al. (2019) Aβ-induced vulnerability propagates via the brain's default mode network. Nature Communications. 10: 2353|
|Malcolm JC, Breuillaud L, Do Carmo S, et al. (2019) Neuropathological changes and cognitive deficits in rats transgenic for human mutant tau recapitulate human tauopathy. Neurobiology of Disease|
|Cuello AC, Hall H, Do Carmo S. (2019) Experimental Pharmacology in Transgenic Rodent Models of Alzheimer's Disease. Frontiers in Pharmacology. 10: 189|
|Cuello AC, Pentz R, Hall H. (2019) The Brain NGF Metabolic Pathway in Health and in Alzheimer's Pathology. Frontiers in Neuroscience. 13: 62|